Session Details

Regeneus' Novel Allogenic Stem Cell Platforms For Musculoskeletal and Neuropathic Pain Disorders (Global Showcase Presentation Hosted By Regeneus Ltd)
Thursday, May 30, 2019 12:45 PM - 01:00 PM
ISCT Global Showcase Lounge (Exhibit Hall)
Speaker:
Charlotte Morgan, PhD , Head of R&D, Regeneus Ltd, Australia

Regeneus is an Australian based clinical stage regenerative medicine company, focused on musculoskeletal and Neuropathic pain indications. Our leading technology platform Progenza is an Adipose derived MSC product combined with MSC secretions. A Phase 1 clinical study in Knee Osteoarthritis met primary and secondary endpoints in pain reduction and positive signs of disease modification. Positive pre-clinical pain study data has also been achieved in preparation for a clinical study in Neuropathic pain.